Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Ritodrine HCl (DU21220; DU21220; ST51015115; ST-51015115; Pre-Par; Utopar), the hydrochloride salt of ritodrine, is a β-2 adrenergic receptor agonist used to treat premature labor.
Targets |
β2-adrenergic receptor
|
---|---|
References |
|
Molecular Formula |
C17H22CLNO3
|
|
---|---|---|
Molecular Weight |
323.81
|
|
Exact Mass |
323.13
|
|
Elemental Analysis |
C, 63.06; H, 6.85; Cl, 10.95; N, 4.33; O, 14.82
|
|
CAS # |
23239-51-2
|
|
Appearance |
Solid powder
|
|
SMILES |
C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O.Cl
|
|
InChi Key |
IDLSITKDRVDKRV-XHXSRVRCSA-N
|
|
InChi Code |
InChI=1S/C17H21NO3.ClH/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13;/h2-9,12,17-21H,10-11H2,1H3;1H/t12-,17-;/m0./s1
|
|
Chemical Name |
4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0882 mL | 15.4412 mL | 30.8823 mL | |
5 mM | 0.6176 mL | 3.0882 mL | 6.1765 mL | |
10 mM | 0.3088 mL | 1.5441 mL | 3.0882 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00679705 | Completed | Drug: Ritodrine Drug: Atosiban Drug: Placebo |
Healthy | University Hospital, Ghent | May 2008 | Phase 1 |
NCT02538718 | Completed | Drug: MgSO4 Drug: YTP(Ritodrine) |
Preterm Labor | Seoul National University Hospital |
September 22, 2015 | Not Applicable |
NCT03040752 | Completed | Drug: Nifedipine 20 Mg Drug: Ritodrine Oral Tablet |
Preterm Birth | Cairo University | January 2015 | Phase 4 |
NCT00290173 | Completed | Drug: efficacy of oral ritodrine in maintaining uterine quiescence |
Pregnancy | University of Zagreb | August 2005 | Not Applicable |
Characteristics of Treatment in the Ritodrine and Placebo Groups. N Engl J Med . 1992 Jul 30;327(5):308-12. td> |
There were no maternal deaths. There were 48 deaths among the 771 infants (Table 4), including 21 stillbirths (10 in the ritodrine group and 11 in the placebo group). N Engl J Med . 1992 Jul 30;327(5):308-12. td> |
At a corrected postnatal age of 18 months, the 246 children born to women in the two groups who were randomly selected to return for follow-up evaluations had similar scores on the Bayley Psychomotor Development Index (ritodrine, 110.9±16.8; placebo, 108.7±15.5). N Engl J Med . 1992 Jul 30;327(5):308-12. td> |